[1] Siegel RL, Miller KD, Fuchs HE, Jemal A.Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. [2] Dekker E, Tanis PJ, Vleugels JLA, et al.Colorectal cancer[J]. Lancet, 2019, 394(10207): 1467-1480. [3] Amawi H, Sim HM, Tiwari AK, et al.ABC Transporter-Mediated Multidrug-Resistant Cancer[J]. Adv Exp Med Biol, 2019, 1141: 549-580. [4] Schlattner U, Tokarska-Schlattner M, Wallimann T.Mitochondrial creatine kinase in human health and disease[J]. Biochim Biophys Acta, 2006, 1762(2):164-180. [5] Onda T, Uzawa K, Endo Y, et al.Ubiquitous mitochondrial creatine kinase downregulated in oral squamous cell carcinoma[J]. Br J Cancer, 2006, 94(5):698-709. [6] DeLuca M, Hall N, Rice R, Kaplan NO. Creatine kinase isozymes in human tumors[J]. Biochem Biophys Res Commun, 1981, 99(1):189-195. [7] Kanemitsu F, Kawanishi I, Mizushima J, Okigaki T.Mitochondrial creatine kinase as a tumor-associated marker[J]. Clin Chim Acta, 1984, 138(2):175-183. [8] Kornacker M, Schlattner U, Wallimann T, et al.Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis[J]. Int J Cancer, 2001, 94(4):513-519. [9] Tsung SH.Creatine kinase activity and isoenzyme pattern in various normal tissues and neoplasms[J]. Clin Chem, 1983, 29(12):2040-2043. [10] Pang B, Zhang H, Wang J, et al.Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression[J]. Prostate, 2009, 69(11):1176-1187. [11] Cimino D, Fuso L, Sfiligoi C, et al.Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues[J]. Int J Cancer, 2008, 123(6):1327-1338. [12] Qian XL, Li YQ, Gu F, et al.Overexpression of ubiquitous mitochondrial creatine kinase (uMtCK) accelerates tumor growth by inhibiting apoptosis of breast cancer cells and is associated with a poor prognosis in breast cancer patients[J]. Biochem Biophys Res Commun, 2012, 427(1):60-66. [13] Kellokumpu I, Kairaluoma M, Mecklin JP, et al.Impact of Age and Comorbidity on Multimodal Management and Survival from Colorectal Cancer: A Population-Based Study[J]. J Clin Med, 2021, 10(8):1751. [14] Najumudeen AK, Ceteci F, Fey SK, et al.The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer[J]. Nat Genet, 2021, 53(1):16-26. [15] Zhou Y, Bian S, Zhou X, et al. Single-Cell Multiomics Sequencing Reveals Prevalent Genomic Alterations in Tumor Stromal Cells of Human Colorectal Cancer [J]. Cancer Cell, 2020, 38(6):818-828.e5. [16] De Wever O, Pauwels P, De Craene B, et al.Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front[J]. Histochem Cell Biol, 2008, 130(3): 481-494. [17] Mayer IA, Arteaga CL.The PI3K/AKT Pathway as a Target for Cancer Treatment[J]. Annu Rev Med, 2016, 67:11-28. [18] Lien EC, Dibble CC, Toker A.PI3K signaling in cancer: beyond AKT[J]. Curr Opin Cell Biol, 2017,45:62-71. [19] Yap TA, Garrett MD, Walton MI, et al.Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises[J]. Curr Opin Pharmacol, 2008, 8(4): 393-412. |